Mizuho Securities analyst Mara Goldstein assigned a Buy rating to Arcus Biosciences (RCUS) yesterday and set a price target of $40.00. The company’s shares closed last Friday at $20.27.
According to TipRanks.com, Goldstein is a 4-star analyst with an average return of 9.5% and a 39.7% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Iovance Biotherapeutics, and Neoleukin Therapeutics.
Currently, the analyst consensus on Arcus Biosciences is a Moderate Buy with an average price target of $36.00, implying a 70.7% upside from current levels. In a report issued on November 6, Leerink Partners also maintained a Buy rating on the stock with a $41.00 price target.
See today’s analyst top recommended stocks >>
Based on Arcus Biosciences’ latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $1.75 million and GAAP net loss of $45.07 million. In comparison, last year the company earned revenue of $1.75 million and had a GAAP net loss of $28.09 million.
Based on the recent corporate insider activity of 14 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of RCUS in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Arcus Biosciences, Inc. engages in the development and commercialization of immunotherapies. The firm compete in the segments of the pharmaceutical, biotechnology and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.
